Vaccines Against Infectious Diseases – VID
The Vaccines Against Infectious Diseases (VID) study section reviews applications concerned with vaccine late-stage development against all classes of pathogens (except HIV). A feature of applications reviewed in this study section is the measurement of vaccine efficacy. This study section also reviews applications focusing on the improvement and safety of vaccines already approved for human or veterinary use. Applications often involve animal models, human samples, or human subjects.
Review Dates
Topics
- Vaccines against pathogens of clinical or veterinary interest, including bacteria, viruses (except HIV), parasites, fungi, bacterial toxins, and pathogenic agents that have biodefense implications
- Pre-clinical and clinical vaccine testing, including protection from disease, and safety studies
- Vaccine formulation and production for all classes of vaccines (inactivated vaccines, live-attenuated vaccines, mRNA vaccines, toxoid vaccines, viral vector vaccines, and subunit, recombinant, polysaccharide, and conjugate vaccines).
- Vaccine platform and delivery systems optimization
- Safety studies and modifications of existing vaccines
Shared Interests and Overlaps
- There are shared interests with Early Development of Vaccine against Infectious Diseases [DCAI (89)]. Applications that emphasize early to mid-stage development of vaccines may be reviewed in DCAI (89). Applications that emphasize late-stage development and measure vaccine efficacy, safety, or improvement may be reviewed in VID.
- There are shared interests in immune responses to pathogens with Immunity and Host Defense (IHD). Applications that emphasize basic immunological studies, such as mechanistic studies of the innate, systemic, and mucosal immune responses to microbial organisms may be reviewed by IHD. Applications that emphasize testing of vaccines may be reviewed in VID.
- There are shared interests in nucleic acid-based vaccine development with Drug and Biologic Therapeutic Delivery (DBTD) and Nucleic Acid Therapeutic Delivery [BBBT (81)]. Applications that emphasize novel methods for vaccine delivery, with a focus on bioengineering principles, may be reviewed in DBTD or BBBT (81). Applications that emphasize vaccine testing and efficacy may be reviewed in VID.
- There are shared interests in studies of vaccines approved for human use with Etiology, Diagnostic, Intervention and Treatment of Infectious Diseases (EDIT). Applications that focus on mechanisms of vaccine efficacy may be reviewed in EDIT. Applications that focus on vaccine safety or on modifying the composition of existing vaccines may be reviewed in VID.
- There are shared interests with Immunobiology of Transplantation and Alloimmunity (ITA). Applications that focus on the impact of immunosuppressive therapies on immune responses to vaccine and/or vaccine performance may be reviewed in ITA. Applications that focus on general approaches to improve the performance of existing vaccines may be reviewed in VID.
